Jiangsu Nhwa Pharmaceutical Co.Ltd(002262) : there are more than 70 products under development. Trv-130 is expected to get the production approval before and after the end of the year

On the afternoon of April 8, Jiangsu Nhwa Pharmaceutical Co.Ltd(002262) ( Jiangsu Nhwa Pharmaceutical Co.Ltd(002262) ) held an online performance briefing. Dong Secretary Duan Baozhou said that the company’s new opioid postoperative analgesic trv130 is expected to get production approval around the end of this year. According to the 2021 annual report, the company is currently researching more than 70 scientific research projects. In 2021, it invested 402 million yuan in scientific research, an increase of 50.89% over the previous year. Among them, in terms of innovative drug research and development, the company has more than 20 new drug research and development projects; In terms of research and development and consistency evaluation of key generic products, 20 consistency evaluation projects were carried out; 3 products with generic drug production approval; Generic drugs are under review in 4 projects.